生物活性：Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Regorafénib N-oxyde-d3(M2) 相关抗体:
Phospho-PDGFR beta (Y740) Antibody
PDGFR alpha Antibody
PDGF B Antibody (YA1556)
PDGFR beta Antibody (YA1925)
FMO3 Antibody (YA1992)
Phospho-PDGFR beta (Tyr740) Antibody (YA3062)
分子量：501.83
Formula：C21H12D3ClF4N4O4
CAS 号：1333489-03-4
非标记 CAS：835621-11-9
中文名称：瑞格非尼 N-氧化物(M2代谢物)杂质13-d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (525 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Allard M, et al. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. J Pharm Biomed Anal. 2017 Aug 5;142:42-48.
 [Content Brief]